CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Last trade$5.19
Day change+$0.34 (+7.01%)
Day range$4.50 – $5.36
Volume21,737
Market cap$15M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$15.28M
Price / earnings
—
Price / book
-20.35×
Price / sales
0.41×
EV / sales
0.76×
EV / EBITDA
-2.62×
Profitability
Earnings per share
-$5.78
Return on assets
-47.98%
Return on equity
2,425.17%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-22.96×
Current ratio
0.66×
Quick ratio
0.5×
Cash ratio
0.18×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.3M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CTSO, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$9.63M
$8.86M
$9.23M
$9.49M
$9.62M
$8.73M
$9.15M
$8.61M
Cost of revenue
$2.58M
$2.73M
$2.43M
$2.82M
$2.8M
$2.52M
$2.9M
$3.36M
Gross profit
$7.05M
$6.13M
$6.8M
$6.67M
$6.81M
$6.21M
$6.26M
$5.26M
Selling, general and administrative
$7.96M
$8.15M
$9.44M
$8.61M
$9.17M
$8.43M
$7.64M
$8.26M
Research and development
$1.45M
$1.03M
$1.24M
$918K
$1.26M
$1.66M
$2.02M
$1.83M
Total operating expenses
$9.69M
$9.17M
$11.19M
$9.53M
$10.43M
$10.1M
$9.65M
$10.09M
Operating income
-$2.64M
-$3.04M
-$4.39M
-$2.86M
-$3.62M
-$3.89M
-$3.4M
-$4.83M
Interest expense
-$868K
-$857K
$0
$0
-$616K
-$605K
$0
$0
Income before taxes
-$4.42M
-$5.13M
-$5.5M
-$3.57M
$1.95M
-$1.48M
-$9.26M
-$2.77M
Income taxes
$0
$0
$0
-$401K
$0
$0
-$1.69M
$0
Net income
-$4.42M
-$5.13M
-$5.5M
-$3.17M
$1.95M
-$1.48M
-$7.57M
-$2.77M
Net income attributable to common shareholders
-$4.42M
-$5.13M
-$5.5M
-$3.17M
$1.95M
-$1.48M
-$7.57M
-$2.77M
EBITDA
-$2.02M
-$2.69M
-$3.52M
-$2.5M
-$3.21M
-$3.52M
-$3.01M
-$4.45M
Basic earnings per share
-$1.40
-$1.60
-$1.75
-$1.00
$0.60
-$0.40
-$3.01
-$1.00
Diluted earnings per share
-$1.40
-$1.60
-$1.89
-$1.00
$0.60
-$0.40
-$3.01
-$1.00
Recent news
Company coverage with links to the original publishers.
CytoSorbents reported a 3% decrease in Q1 2025 revenue, but improved operating loss and net loss. The company is making progress with its DrugSorb-ATR device, which is under review by the FDA and Health Canada.
CytoSorbents Corporation received a denial letter from the FDA regarding its De Novo Request for DrugSorb-ATR, a device designed to reduce bleeding in CABG patients on the antiplatelet drug Brilinta. The company plans to continue working with the FDA to resolve the remaining issues and obtain regulatory approval.
CytoSorbents reported strong Q4 2024 preliminary results, with product revenue growth of 22-25% and gross margin improvement to 70%. However, the company's shares dipped despite the positive outlook, as it prepares to enter the North American market with its DrugSorb-ATR product pending regulatory approvals.
CytoSorbents Corporation reported strong preliminary Q4 2024 financial results, with product revenue growth estimated at 22-25% year-over-year and gross margin improving to around 70%. The company also provided updates on its regulatory progress for DrugSorb-ATR, an investigational device to reduce perioperative bleeding in CABG surgery patients.
CytoSorbents shares are trading 21% higher after the company entered into a new $20 million credit facility with Avenue Capital Group to support its CytoSorb® franchise and aid in FDA and Health Canada applications for DrugSorb™-ATR.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.